Urol. praxi, 2011; 12(3): 189-190

Kontrastní látky s obsahem gadolinia a nefrogenní systémová fibróza

MUDr.Jana Mladá, MUDr.Petra Vacková
Státní ústav pro kontrolu léčiv, Praha

Možná souvislost mezi nefrogenní systémovou fibrózou (NSF) a kontrastními látkami s obsahem gadolinia (GdCA) byla poprvé popsána

v lednu 2006 (1). Od té doby případů NSF přibývá a podezření na možnou souvislost s GdCA bylo potvrzeno. Jsou k dispozici doporučení

k prevenci tohoto vzácného, ale závažného onemocnění.

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mladá J, Vacková P. Kontrastní látky s obsahem gadolinia a nefrogenní systémová fibróza. Urol. praxi. 2011;12(3):189-190.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21(4): 1104-1108. Erratum 2006; 21(6): 1745. Go to original source... Go to PubMed...
    2. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol clin N Am 2009; 47: 833-840. Go to original source... Go to PubMed...
    3. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, Leboit PE. Scleromyxoedema-like cutaneous disease in renaldialysis patients. Lancet, 2000; 356: 1000. Go to original source... Go to PubMed...
    4. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990; 8: 467-481. Go to original source... Go to PubMed...
    5. Heinz-Peer G, Neruda A. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease; European Journal of Radiology 2010; 76: 129-134. Go to original source... Go to PubMed...
    6. Bartolini ME, Moran GR, Pekar J, et al. An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis Proc Intl Soc Mag Reson Med 2002: 10.
    7. Gibby, et al. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy Invest Radiol 2004; 39: 138-142. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.